Therapeutics targeting a novel pathway to treat acute inflammation and prevent tissue damage.
  • About
  • Science
  • Research and Development Programs
  • News
  • Contact

DecImmune Therapeutics is developing a novel monoclonal antibody aimed at preserving cardiac function following a heart attack. The therapy is designed to be administered during stenting procedures that are typically used to restore blood-flow in response to myocardial infarction. This approach is based on the discovery that blood flow restoration to the heart can trigger a cascade of events that lead to scarring and long-term loss of cardiac function. This pathway, called N2, was discovered and elucidated in the laboratories of the company's founders at Harvard Medical School, Michael Carroll, PhD, and Francis Moore Jr., MD.


DSM and DecImmune Sign Agreement to Develop N2 Pathway Blocking Antibody
Press Release


DecImmune Therapeutics Secures $2.25 Million in Development Funding
Press Release